Company intelligence / Profile preview

Kither Biotech

Ownership: Private
Development stage: Preclinical

Overview

KIT2014 has entered Phase 1 clinical trials as of October 2024. The SAD/MAD study is expected to enroll 72 healthy volunteers and will evaluate up to 6 dose levels of KIT2014 delivered via nebulizer versus placebo.[9]

Therapeutic areas: PulmonologyRare Diseases
Modalities: Small moleculesPeptides
Industry: Biotech

Drug pipeline

2 assets

KIT2014

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kither Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kither Biotech.

Explore the full profile